About TiGenix
TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and a strong clinical stage pipeline of adult stem cell programs. The company’s lead product, ChondroCelect®, for cartilage repair in the knee, is the only approved cell-based product in Europe, and is currently being launched across Europe. TiGenix’s adipose derived allogeneic stem cell platform has been extensively validated. The company is preparing a Phase III clinical trial to treat complex perianal fistula in patients with Crohn’s, has a Phase IIa trial in rheumatoid arthritis ongoing, and will start a Phase I trial to investigate intra-lymphatic administration in autoimmune disorders. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands).
Products
Latest News
15 May 2012 - TiGenix Reports Business & Financial Results for the First Quarter 2012 (EN - NL - FR)
8 May 2012 - TiGenix to Present at Key Conferences - Spring 2012 (EN - NL - FR)
24 April 2012 - TiGenix obtains manufacturing license for European production facility (EN - NL - FR)
17 April 2012 - TiGenix rheumatoid arthritis Phase IIa study successfully passes last safety hurdle (EN - NL - FR)
17 April 2012 - TiGenix completes third and final phase of the Orthomimetics acquisition (EN - NL)
Events
Dag van de Biotechnologie
June 23 2012 - Leuven, Belgium
BIO International Convention
June 18-21 2012 - Boston, US
Request meeting
18th International Stem Cell Therapy Society Annual Meeting
June 7 2012 - Seattle, US
Request meeting
World Stem Cells and Regenerative Medicine Congress
May 21-23 2012 - London, UK
Request meeting
BioEquity
May 15-16 2012 - Frankfurt, Germany
Request meeting